Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leuk Lymphoma. 2017;58(7):1648–1654.
   PubMed Web of Science ®Google Scholar
• Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174(3):382–396.
   PubMed Web of Science ®Google Scholar
• Maynadie M, Girodon F, Manivet-Janoray I, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica. 2011;96(1):55–61.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Ades L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013;37(6):609–613.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013;88(3):201–206.
   PubMed Web of Science ®Google Scholar
• Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–3015.
   PubMed Web of Science ®Google Scholar
• Ricci C, Fermo E, Corti S, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16(8):2246–2256.
   PubMed Web of Science ®Google Scholar
• Schuler E, Schroeder M, Neukirchen J, et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014;38(12):1413–1419.
   PubMed Web of Science ®Google Scholar
• Cervera N, Itzykson R, Coppin E, et al. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. Am J Hematol. 2014;89(6):604–609.
   PubMed Web of Science ®Google Scholar
• Storniolo AM, Moloney WC, Rosenthal DS, et al. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766–770.
   PubMed Web of Science ®Google Scholar
• Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130(2):126–136.
   PubMed Web of Science ®Google Scholar
• Moyo TK, Savona MR. Therapy for chronic myelomonocytic leukemia in a new era. Curr Hematol Malig Rep. 2017;12(5):468–477.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: focus on clinical practice. Mayo Clin Proc. 2016;91(2):259–272.
   PubMed Web of Science ®Google Scholar
• Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995;91(2):403–408.
   PubMed Web of Science ®Google Scholar
• Takubo H, Hattori N, Irie S, et al. [A 45-year-old man with peripheral monocytosis and right hemiparesis]. No To Shinkei. 1998;50(5):481–489.
   PubMedGoogle Scholar
• Aoyama K, Ishikura H, Tsumura H, et al. Meningeal involvement of chronic myelomonocytic leukemia. J Neurol. 2003;250(8):993–994.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Kamesaki H, Amano H, et al. [Meningeal leukemia in the chronic stage of chronic myelomonocytic leukemia]. Rinsho Ketsueki. 1988;29(6):901–906.
   PubMedGoogle Scholar
• Shaikh A, Parulekar M, James B. Acute suprachoroidal haemorrhage with acute angle closure glaucoma as a presenting sign of chronic myelomonocytic leukemia. Eye (Lond). 2002;16(5):651–653.
   PubMed Web of Science ®Google Scholar
• Joubert B, Desestret V, Rheims S. Brain pseudo-tumoral inflammatory lesion associated with chronic myelomonocytic leukemia. J Neurooncol. 2013;113(1):149–150.
   PubMed Web of Science ®Google Scholar
• De Smit E, O’Sullivan E. A diagnostic challenge: chronic myelomonocytic leukaemia and recurrent anterior ischaemic optic neuropathy. Int Ophthalmol. 2013;33(4):415–423.
   PubMed Web of Science ®Google Scholar
• Yeung DF, Hsu R. Expressive aphasia in a patient with chronic myelomonocytic leukemia. Springerplus. 2014;3:406.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2ʹ-deoxycytidine. J Biol Chem. 1982;257(4):2041–2048.
   PubMed Web of Science ®Google Scholar
• Leone G, D’Alo F, Zardo G, et al. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem. 2008;15(13):1274–1287.
   PubMed Web of Science ®Google Scholar
• Rybka J, Stefanko E, Bogucka-Fedorczuk A, et al. Azacitidine in outpatient treatment – single center experience. Contemp Oncol (Pozn). 2015;19(6):467–470.
   PubMed Web of Science ®Google Scholar
• Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2ʹ-deoxycytidine in rabbits and dogs. Cancer Res. 1983;43(2):592–597.
   PubMed Web of Science ®Google Scholar
• Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2ʹ-deoxycytidine in children with acute leukemia. Leuk Res. 1981;5(6):453–462.
   PubMed Web of Science ®Google Scholar
• Prasad BC, Chandra VV, Varaprasad G. Dural metastases in chronic myeloid leukemia presenting as subdural hematoma. Turk Neurosurg. 2012;22(6):777–778.
   PubMed Web of Science ®Google Scholar
• Comanescu A, Rosca E, Bota M, et al. Chronic subdural hematoma in a patient with acute myeloid leukemia and dural metastatic infiltration. Rom J Morphol Embryol. 2008;49(2):259–262.
   PubMed Web of Science ®Google Scholar
• Laigle-Donadey F, Taillibert S, Mokhtari K, et al. Dural metastases. J Neurooncol. 2005;75(1):57–61.
   PubMed Web of Science ®Google Scholar
• Chen CY, Zimmerman RA, Faro S, et al. Childhood leukemia: central nervous system abnormalities during and after treatment. AJNR Am J Neuroradiol. 1996;17(2):295–310.
   PubMed Web of Science ®Google Scholar
• Zahid MF, Barraco D, Lasho TL, et al. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma. 2017;58(6):1488–1493.
   PubMed Web of Science ®Google Scholar
• Peker D, Padron E, Bennett JM, et al. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015;133(2):249–256.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Michel M, Chauveheid MP, et al. Immune thrombocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014;93(6):521–526.
   PubMed Web of Science ®Google Scholar
• Antony-Debre I, Bluteau D, Itzykson R, et al. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood. 2012;120(13):2719–2722.
   PubMed Web of Science ®Google Scholar
• Shiba N, Hasegawa D, Park MJ, et al. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML). Blood. 2012;119(11):2612–2614.
   PubMed Web of Science ®Google Scholar
• Wandt H, Schafer-Eckart K, Greinacher A. Platelet transfusion in hematology, oncology and surgery. Dtsch Arztebl Int. 2014;111(48):809–815.
   PubMed Web of Science ®Google Scholar
• Ochiai H, Yamakawa Y, Ikeda T, et al. [Perioperative management of intracranial hemorrhage related to hematological disease]. No Shinkei Geka. 1998;26(4):331–338.
   PubMedGoogle Scholar
• Etchill EW, Myers SP, Raval JS, et al. Platelet transfusion in critical care and surgery: evidence based review of contemporary practice and future directions. Shock. 2017 May;47(5):537–549.
   PubMed Web of Science ®Google Scholar